Use of GLP-1 RAs, SGLT2 inhibitors, and pioglitazone can be used to improve glycemic control and may reverse steatosis in patients with T2D and NAFLD/NASH [33]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.